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TDP-43 proteinopathy, initially associated with ALS and FTD, is also found in 
30-60% of Alzheimer’s disease (AD) cases and correlates with worsened cognition and 
neurodegeneration. A major component of this proteinopathy is depletion of this RNA-
binding protein from the nucleus, which compromises repression of nonconserved cryptic 
exons in neurodegenerative diseases. To test whether nuclear depletion of TDP-43 may 
contribute to the pathogenesis of AD in cases with TDP-43 proteinopathy, we examined 
the impact of depletion of TDP-43 in populations of neurons thought to be vulnerable in 
AD, and on neurodegeneration in an AD-linked context. Here, we show that TDP-43 
depletion in forebrain neurons accelerates neurodegeneration in an AD mouse model 
independent of the Aβ plaque burden. Moreover, populations of large pyramidal neurons 
in the forebrain that are selectively vulnerable in AD are also vulnerable to TDP-43 
depletion. These findings support a role for nuclear depletion of TDP-43 in the 
pathogenesis of AD and provide strong rationale for developing novel therapeutics to 
alleviate the depletion of TDP-43, creating functional ante-mortem biomarkers for early 
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Alzheimer’s disease (AD) is the most common cause of dementia
1
 and the fifth 
leading cause of death among the elderly in the United States
2
. Dementia is a debilitating 
condition characterized by a progressive loss of cognitive function, behavioral changes, 
and a decline in performing activities of daily living
3
. In AD, these deficits are caused by 
a loss of synapses, and eventually neurons, beginning in the hippocampus and forebrain
4
, 
areas critical for memory, and executive functions like planning and making decisions. 
Eventually, as neurodegeneration spreads to other parts of the brain, patients lose the 
ability to perform basic movements like walking, talking, swallowing, and even 
breathing. The severity of these deficits and the slow progression of the disease mean that 
many AD patients reliant on constant, attentive care for many years, leading to direct and 
indirect health care costs of over $450 billion in 2015
5
. These costs continue to rise as 
more people live longer and effective disease-modifying treatments remain unavailable. 





decade of life, there is evidence that neuronal dysfunction and degeneration begin several 
decades earlier
6,7
. Therefore, once cognitive decline becomes apparent, many synapses 
and neurons have already been lost, and this physical damage is likely irreversible. This 
suggests that understanding the pathogenesis of AD before permanent neuronal damage 
takes place may accelerate the development of effective therapeutics. Significant 
improvements in the development of biomarkers for use in living patients have made 
clinical trials in early and pre-symptomatic stages of AD feasible, potentially improving 





Canonical hypotheses of AD 
The first major hypothesis of AD pathogenesis was the “amyloid cascade 
hypothesis” formalized by Hardy and Higgins in 1992
10
. It posits that extracellular Aβ 
deposits, called plaques, are the primary cause of AD and directly lead to tau 
neurofibrillary tangles, followed by synapse degeneration and cell loss in an essentially 
linear cascade manner. A strong role for Aβ in AD is supported by genetic linkage studies 
showing that mutations in genes responsible for Aβ production (APP, PSEN1) lead to 
inherited forms of AD with nearly complete penetrance
11
. In addition, APOE, which has 
been implicated in Aβ clearance
12,13
, was identified as a strong modifier of AD risk
14,15
. 
Since the amyloid cascade hypothesis was formulated, a large body of evidence has 
accumulated indicating that some form(s) of soluble/diffusible, multimeric Aβ oligomers, 
rather than plaques per se, initiate AD neurodegeneration (reviewed in
16
). Therefore, the 
modern amyloid cascade hypothesis posits that Aβ oligomers are the causal factor in the 
cascade. This process now also includes dysfunctional synaptic plasticity and 
neuroinflammation as important contributors in the disease
16
. Intriguingly, compounds 
that disaggregate Aβ oligomers improve cognition and reduce glial inflammation in AD-
linked mutant mice, even when administered after onset of plaque deposition and 
cognitive deficits
17
, indicating that Aβ-induced damage may be reversible, particularly 
before the onset of tau pathology. Potentially promising Phase II results of a small Aβ 
immunization trial
18




While strong evidence supports a linear progression of disease caused by Aβ in 





First, the risk genes associated with sporadic AD by genome-wide association studies are 
involved in immune function, lipid biology, and endocytosis
8
. While there is reasonable 









regulate various facets of Aβ metabolism in vivo
26
, additional functions have been 
demonstrated for many of these factors that could explain neurodegeneration independent 
of Aβ
27–29
. In addition, several of the AD risk genes are also implicated in 
neurodegenerative diseases with no Aβ pathology
28,30
, which suggests that they do not 
promote dysfunctional Aβ dynamics. Instead, the diversity of function of AD risk genes 
further supports multiple pathogenic factors in sporadic AD. Interestingly, the strongest 
risk factor for AD is aging
5







 can induce 
pathogenic processing of Aβ. Head injury is another major risk factor for AD, 
particularly in individuals carrying the ApoE4 risk allele
35–37
, and can lead to both Aβ 
deposition and tau tangle formation
26
. This “reactive” formation of AD pathology 
indicates that cases of dementia with Aβ and tau pathology can exist where Aβ is a 
byproduct or late contributor, rather than a major driver of disease. Importantly, Aβ-
targeted therapies could be expected to have minimal or no effect on cognitive decline in 
these cases. 
Many clinical findings also support multifactorial etiologies in sporadic AD. First, 
a large proportion (~30%) of clinically diagnosed AD cases do not meet the pathologic 
criteria for plaques and tangles at autopsy
38
. While a common explanation for this is that 
these are misdiagnosed cases of another dementia, others have noted that the assumption 





example, patients carrying the Osaka E693Δ APP mutation produce highly oligomeric Aβ 
that is resistant to proteolytic degradation, but does not form fibrils or plaques
39
. As a 
recent review cogently argues
21
,  
“… to list amyloid deposits as a required part of the definition of [AD] is 
supported neither by the data nor by the clinical experience. It is the 
equivalent of saying that once plaques are found in the coronary arteries, a 
person is having a heart attack and, if there are no plaques in the arteries, 
no myocardial event can be defined as a heart attack. This is not a useful 
concept. Rather, in both heart and brain, the plaques define risk, not 
disease.”  
Though plaques can be a useful visible indicator that damaging oligomeric Aβ is present 
at high levels in the brain, they do not correlate well with pathogenesis or cognitive 
decline
40,41
. As in the case of heart attack, the same clinical presentation of AD (or the 
same functional failure of a particular population of neurons) may arise in different 
individuals through multiple pathogenic mechanisms. Additionally, multiple independent 
etiologies have been well-demonstrated in cancers
42–44
 which, like AD, have a high 
degree of complexity and have resisted treatment efforts. 
The second clinical finding that supports multifactorial etiologies for AD is that 
20-40% of cognitive normal individuals are nonetheless pathologically indistinguishable 
from those with severe clinical symptoms of AD
38,45
. This suggests that Aβ and tau 
pathologies are not sufficient to cause “the complex symptomatology of AD”
21
, and that 
other pathogenic factors may contribute. Indeed, recent work showed that non-canonical 
pathologies occur in up to 75% of AD cases
46,47
 including TDP-43 proteinopathy, α-
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synuclein “Lewy bodies”, and tau “Pick bodies” that each contribute to 
neurodegeneration in separately classified diseases
48–50
. Together, these findings suggest 
that Aβ is one of many initiators of sporadic AD as part of a complex set of conditions 
that lead to cognitive failure
9,21
.  
TDP-43 as a non-canonical pathogenic factor in AD 
Increasing evidence suggests that nuclear depletion of the transactivation response 
element DNA-binding protein 43 (TDP-43) may be a non-canonical pathogenic factor in 
AD. As noted previously, TDP-43 proteinopathy, characterized by nuclear depletion and 





. Notably, TDP-43 proteinopathy is strongly associated with worsened cognition in 
AD cases
52







 that have been shown to impact neurofilament stability
59
 and synaptic 
plasticity
53
. Tdp-43 is an essential gene
60
 that regulates a large number of pre-mRNAs
61
 
and its protein level is tightly controlled through auto-regulation
62





 expression of TDP-43
 
lead to early death, while animals with 
heterozygous knockout of Tdp-43 maintain normal protein levels
60
.  
TDP-43 is known to migrate from the nucleus to the cytoplasm under conditions 
of stress
54,55
, forming normally short-lived protein-RNA complexes called stress 
granules. Interestingly, other RNA binding proteins that take part in stress granule 
formation have been shown to be susceptible to fibrillization during this process
64,65
, 
indicating one mechanism by which TDP-43 might be depleted from the nucleus in 
sporadic AD. These fibrils shares structural commonalities with Aβ and tau aggregates in 
AD, and also with α-synuclein aggregates in Parkinson’s, suggesting that a common age-
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related cellular mechanism may lead to aberrant aggregation of proteins in many 
neurodegenerative diseases of aging
66,67
. 
Previously, we found that TDP-43 is a splicing repressor of nonconserved cryptic 
exons in multiple cell types, including neurons, and that this function is compromised in 
the neurodegenerative disease spectrum of amyotrophic lateral sclerosis and 
frontotemporal dementia (ALS-FTD)
68
. Specifically, nuclear depletion of TDP-43 leads 
to incorporation of nonconserved cryptic exons that often induce nonsense mediated 
decay of the associated mRNAs, potentially altering the proteome of TDP-43 depleted 
cells. Importantly, we recently found that TDP-43-associated cryptic exons are also 
incorporated in the brains of AD cases with TDP-43 pathology (Chen et al., 
unpublished), indicating that nuclear depletion of TDP-43 may indeed contribute to the 
pathogenesis of AD. In addition, current clinico-pathologic evidence indicates that TDP-
43 proteinopathy occurs independent of Aβ; the presence of one pathology does not make 
the other more likely to occur
47
. This suggests that TDP-43 proteinopathy and Aβ 
pathology may mark the presence of separate pathogenic mechanisms that contribute 
independently to neurodegeneration. Specifically, we hypothesize that nuclear depletion 
of TDP-43 contributes to AD pathogenesis in cases with TDP-43 proteinopathy. The 
outcome of studies to test this hypothesis, whether positive or negative, could inform 
therapeutic development as well as the design and interpretation of clinical trials. For 
example, up to 75% of AD cases have TDP-43 dysfunction
52
 that may require treatment 
separate from Aβ-related dysfunction. If they contribute equally to disease pathogenesis, 
clinical trials of Aβ-targeting therapies that do not exclude or stratify TDP-43-affected 
patients would have dramatically reduced power, and may fail even if the therapy is 
7 
 
effective against Aβ. Conversely, if depletion of TDP-43 does not contribute to AD 
pathogenesis, then continuing failures of current Aβ-directed clinical trials would further 
support the idea that the amyloid cascade hypothesis is not sufficient to explain AD 
pathogenesis. As this question has far-reaching consequences for therapeutic 
development, experimental models that can test these hypotheses are of great interest.   
Modeling AD pathogenesis in mice 
Mechanistic understanding of AD pathogenesis is crucial for the efficient 
development of therapeutic strategies. Genetically modified mice allow researchers to 
study various facets of AD in an intact mammalian system, and over 100 such models 
have been developed to date (alzforum.org/research-models). Genetically modified mice 
are particularly well-suited for studying gene function and the contributions of broad cell 
types (neurons, microglia, etc.) to disease pathogenesis. Most AD models contain 
alterations in one or more AD-linked genes that encode or process aggregative proteins 
characteristic of the disease; APP (50%), PSEN1 (23%), MAPT (tau) (19%), and ApoE 
(8%) (www.alzforum.org/research-models). Of these, 29 models overexpress or knock-in 
mutant human APP. Though many of these models develop plaques with regional 
specificity that is very similar to human AD
69–79
, plaque formation is not necessary to 
produce cognitive deficits
80–82
. In addition, though these models generally exhibit very 
mild, if any, neuron loss
70,81




One of the most commonly used mouse models, developed by Dr. David Borchelt 
and co-workers,  is the APPswe/PS1ΔE9 line, carrying two AD-linked mutations (APP 
K595N/M596L and PSEN1 deletion of exon 9) in a humanized APP sequence expressed 
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under the control of the mouse prion promoter
84
. These mutations lead to an increased 
Aβ42/40 ratio in the brain
84,85
, and visible Aβ plaques begin to develop around 4 months 
of age
85
. In addition, these mice display several other phenotypes characteristic of AD, 







, and cognitive deficits
89,91
. Interestingly, several studies have reported the 
ability of various Aβ-targeting interventions to reverse degenerative phenotypes, usually 
back to wild-type levels, even after extensive physical damage has taken place
17,92
. 
However, whether these degenerative phenotypes are also reversible in the human disease 
remains unclear, and current Aβ-targeting trials in humans should provide further data to 
address this question. Importantly, increased tau phosphorylation also occurs in these 
mice
89,90
, though frank tangles (a structurally-defined form detected using the Gallyas 
silver stain
93
) do not form. This lack of tangles is a common finding among AD-linked 
mutant mice
94
, and has raised further concerns about the accuracy of the amyloid cascade 
hypothesis and its proposition that Aβ directly stimulates the formation of tau tangles.  
To further explore the relationship between Aβ and tau, additional models co-
expressing AD-linked mutations and human tau were developed. Disappointingly, mice 
overexpressing wild-type human tau did not form tangles, and the phospho-tau 
aggregates that did form did not require AD-linked mutations
95
. However, these 
experiments did indicate that Aβ was capable of initiating the hyper-phosphorylation of 
tau that presumably is a precursor to its conformational shift into tangles. Shortly after, 
the LaFerla group developed the 3xTg mouse model expressing mutated P301L 4-repeat 
tau linked to frontotemporal dementia (FTD)
96
 along with two AD-linked mutations. 





However, the relevance of this model to AD is disputed since tau P301L can form tangles 




Since that time, our group has shown that expressing the 4-repeat fragment of 
wild-type human tau in APPswe/PS1ΔE9 leads to age-dependent tau tangles, which do not 
occur with the tau fragment alone (Tong Li, unpublished). For the first time, our group 
has provided strong evidence that Aβ oligomers can indeed precipitate tangle formation 
in wild-type human tau, and that tangle formation accelerates neurodegeneration and 
cognitive deficits compared to AD-mutant mice alone. Importantly, in this novel model 
Aβ appears to drive the formation of tangles in wild-type human tau, which then induces 
the pathological conversion of endogenous mouse tau that can spread throughout the 
brain. Additionally, this is the first evidence that tangle formation of wild-type human tau 
can occur in the mouse brain, and can, therefore, be studied and manipulated in this 
system. However, further experiments are required to truly establish that Aβ oligomers 
drive pathology and neurodegeneration in these models, rather than another factor related 
to the AD-linked mutations. For example, administration of Aβ-targeting antibodies in 
APP/PS1/tau4R mice at an early age should prevent tau tangle formation, and would 
establish Aβ as the causative agent.  
In summary, recently developed mouse models now recapitulate both Aβ 
oligomer and tau tangle pathologies and allow more detailed study of the amyloid 
cascade hypothesis. However, as discussed previously, there is now strong evidence that 
Aβ and tau may be among many factors that can drive AD pathogenesis, particularly in 
sporadic AD cases. Therefore, experimental models are required that allow further study 
10 
 
of putative non-canonical pathogenic factors and their contributions to 
neurodegeneration. Increasing evidence indicates that nuclear depletion of TDP-43 may 
also contribute to AD pathogenesis in a large population of AD cases, as described above. 
If so, we hypothesize that depletion of TDP-43 should lead to selective vulnerability in 
populations of neurons affected by AD, and should accelerate neurodegeneration in an 
AD-linked mammalian context. To investigate these questions, we employed the 
tamoxifen-inducible Cre
ER
 recombinase system to conditionally ablate Tdp-43 in 
forebrain neurons of wild-type and APPswe/PS1dE9 mice. In order to manage the 
complexity of the experimental model, we did not include tau as a facet in these initial 
studies. In addition, our interest in modeling the earliest stages of AD pathogenesis was 
most consistent with examining potential interactions between TDP-43 depletion and Aβ, 
rather than with tau which is thought to occur at a later stage of disease
8
. We focused our 
studies on the hippocampus and layer V of the cortex, two regions where degeneration 
correlates strongly with cognitive decline in early AD
100,101





All experiments were performed under an approved protocol and complied with 
regulations of the Animal Care and Use Committee at Johns Hopkins University School 
of Medicine. Forebrain depletion of TDP-43 in the adult mouse (mus musculus) was 




 (cT) mice with loxP sites 
flanking Tdp-43 exon 3, allowing tamoxifen-induced recombination in excitatory 
forebrain neurons at maturity (Fig. 1a). Mature forebrain depletion of TDP-43 is 
consistent with the late onset of AD and regional specificity of neurodegeneration and 
TDP-43 proteinopathy in patients
40,102–105
. It is also necessary for these studies because 
constitutive knockout of TDP-43 is embryonically lethal, and heterozygous knockout 






 (cT) mice 
were generated and bred with the APPswe/PS1dE9 (AP) line (purchased from Jackson 




;APPswe/PS1dE9 (cTAP) mice on 
a C57BL/6J background, as well as littermate controls. Our breeding strategy is described 
in Fig. 1b. We utilized females exclusively because of sex differences in the AP mouse 
model
106,107
. Animals were genotyped at weaning, and animals of the genotype of 
interests were kept along with an equal number of littermate controls (4 mice/cage), and 
other pups in the litter were sacrificed. Oral tamoxifen was administered at an average 
40mg/kg/day for a four week period beginning at p42-46, after mice reached 
developmental maturity
108





. No other tests, drug administration, or surgery were 
performed on these animals.  
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Studies were conducted in brain tissue from mice aged 3 to 14 months, collected 
from >30 litters over 15 months. At the appropriate age, mice were deeply anesthetized 
using 200μL/25g of 15% chloral hydrate, then perfused briefly with ice cold PBS. The 
brains were removed and one hemisphere was post-fixed in 4% paraformaldehyde for 24 
hours. The other hemisphere was dissected into regions (cortex, hippocampus, 
cerebellum) and individually stored at -80°C. For electron microscopy, one animal of 
each genotype was perfused with 4% paraformaldehyde following the PBS perfusion. 
The brains were removed and placed in 4% paraformaldehyde + 2% glutaraldehyde for 
18 hours. A <3mm
3
 region containing the CA1 was then dissected out and processed for 
electron microscopy using standard procedures by the Johns Hopkins School of Medicine 
Microscope Facility Core. 
Immunoblot and ELISA  
Hippocampal tissue was homogenized in 10 volumes of ice cold RIPA buffer 
supplemented with 1x Protease inhibitor cocktail (Roche) and 1x phosphatase inhibitor 
(PhosSTOP), followed by centrifugation at 12,000xg for 20 min at 4°C. Alternately for 
ELISA, hippocampal tissue was homogenized in 8 volumes of 5M Guanidine HCl, then 
processed for ELISA using the Thermo Fisher human Aβ 42 kit (KHB3441) according to 
the manufacturer’s instructions. Protein levels in the supernatant were determined using 
the BCA assay and 15μg of protein was loaded onto 4-12% or 10% Bis-Tris gels (Novex) 
along with 10uL SeeBlue Plus 2 pre-stained protein standard (Thermo Fisher), and 
transferred onto PVDF membrane. Membranes were probed with antibodies to 
synaptophysin (1:15,000, Abcam SY38/ab8049], PSD-95 (1:5000, NeuroMab K28/43), 
gephyrin (1:1000, BD Transduction Labs 610585), β-tubulinIII (1:30,000, Sigma T2200), 
13 
 
Cox1 (1:1000, Thermo Scientific PA5-26688), Tecpr1 (1:2000, Cell Signaling D6C10), 





] (1:5000, Invitrogen 44604G), and Atg7 (1:2500, R&D Systems 
MAB6608). Band densitometry was quantified using ImageJ software on unaltered 
images, and normalized to total protein loaded using ponceau stain, unless otherwise 
noted. All samples were run at least twice to confirm consistency of the assay and 
validity of the observed effect; each data point represents the average of two independent 
blot results.  
To assess the levels of pre-fibrillar and fibrillar oligomers we used the 
conformation specific antibodies A11 (Invitrogen AHB0052) and OC Millipore 
AB2286), respectively
109
. We homogenized cortex tissue in PBS + 1x Halt protease 
inhibitor (Thermo Fisher) at 4.5 months of age, when AP mice have visible plaque but 
cTAP mice do not. Homogenates were centrifuged at 100,000xg to isolate soluble 
oligomers
109
, and supernatant was spotted onto membranes for standard dot blotting 
procedures. 
Immunohistochemistry and Immunofluorescence 
Brain hemispheres were post-fixed for 24hr in 4% paraformaldehyde, then 
removed to fresh PBS for 24hrs 2x. Hemispheres were sectioned in 10μm serial sections, 
then de-paraffinized and rehydrated. Antigen retrieval was performed in 10mM sodium 
citrate by boiling for 5 minutes, then endogenous peroxidases were inactivated with 0.3% 
sodium hydroxide for 30 minutes. Slides were blocked in 5% normal goat serum, or using 
the mouse on mouse staining kit (Vector Labs BMK-2202). Primary antibodies used 
were: 4G8 (1:1000, BioLegend 800702), TDP-43 N-terminal (1:500, Proteintech 10782-
14 
 
2-AP) and SMI-31 (1:2000 IHC/ 1:1200 IF, Biolegend smi-31r). Secondary antibodies 
were either biotinylated for subsequent avidin binding and DAB reaction, or were 
conjugated to fluorescent epitopes (Alexa Fluor 488 and 564, 1:200).Hematoxylin or 
DAPI were used as nuclear counterstains.  
Immunofluorescent images were taken on a Zeiss LSM 510 confocal microscope 
using a 63x oil objective in the Multiphoton Imaging Core of the Johns Hopkins School 
of Medicine, Department of Neuroscience. An Argon/2 laser was used for 488nm 
detection (transmission 24.8%, gain 541, amplifier offset, -0.017) and a DPSS laser was 
used for 561nm detection (transmission 37.8%, gain 621, amplifier offset -0.062). 
Stereology 
Brain volume, plaque burden and neuron counts were assessed using unbiased 
stereological methods with Stereo Investigator software. Brain region volumes were 
estimated using the Cavalieri probe (counting frame 150x150μm, grid spacing 200μm) in 
3 sections/animal spaced 360μm apart. Plaque burden was estimated using the Area 
Fraction Fractionator probe (counting frame: cortex 300x350μm, cerebellum and 
hippocampus 200x250μm, grid spacing 15μm) in 3 sections/animal spaced 360μm apart. 
Neuron counts of hippocampal areas CA3/2, CA1 and DG were estimated by counting 
the number of neuron nuclei per region in 10 sections/animal spaced 150um apart. As all 
tissue was cut in 10μm thin sections, an optical disector method was not used, however, 
these hippocampal layers and neuronal nuclei sizes are highly uniform which minimizes 
the caveats of using a simple count.  
15 
 
RNA sequencing functional analysis 




mice were obtained from 
Jeong et al. (unpublished). The following exclusion criteria were applied to generate a list 
of the most affected gene products: genes were excluded if the cryptic exon was not 
included in at least 50% of the total RNA generated, or if the RNA fold-change was 
greater than 1.5. These changes reduced the dataset to either heavily downregulated 
RNAs or those with an RNA population containing at least 50% of the cryptic exon; 
qualities that make them more likely to exert a functional effect on the cell. These 
exclusion criteria reduced the list from >100 transcripts to 30. The functional categories 
of the corresponding genes were determined by a manual literature search and are 
presented in Table 1. Three genes had unclear functions and were excluded from the final 
list.  
Randomization and blinding 
 All animals received tamoxifen treatment. No randomization was used to assign 
animals to groups for data collection and processing. Rather, animals of each genotype 
were collected at the appropriate age in batches containing approximately equal 
representation of each genotype. Tissue from each age group was processed in a single 
batch when possible, or in multiple batches containing equal numbers of animals from 
each genotype. During data collection and analysis, the investigator was blinded to 
genotype by assigning an unrelated individual number to each animal at weaning. 
Statistical analysis 
Sample power calculations were performed using SPSS Sample Power 3.0. 
Between groups we were interested in measuring mean differences of at least 25%, and 
16 
 
estimated a standard deviation of 15%. Using these criteria, a per group sample size of 8 
animals has an estimated 87% power. For larger mean differences of at least 40%, a per 
group sample size of 5 animals has an estimated 96% power. Therefore, for most 
statistical analyses the final sample size was n>8, and all were n≥5. Specific sample sizes 
for each graph are reported in legends, and represent biological replicates (# mice/group).  
Data were organized and analyzed using SPSS Statistics 23.0. Data were analyzed with 
Univariate ANOVA by genotype within each age group. A 4(genotype) x 3(age) design 
could not be used due to violations of heterogeneity of variances across age groups. 
Boxplots showed the median, interquartile range (box) 1.5 interquartile range (whiskers), 
outliers (○), and extreme cases (◊) of individual variables for each genotype. Normality 
was validated by ensuring that the |skew/standard error skew|<2 for each group, and 
Welch’s test was used instead of ANOVA if normality was violated in one or more 
groups. When dependent variables were found significant across genotypes, we used 
Gabriel post-hoc tests (as groups had slightly unequal sample sizes), or Games-Howell 
when homogeneity of variances was violated. Post-hoc comparisons are paired with “wt”, 
unless otherwise specified. Unpaired t-tests (two-tailed) are reported when only two 
groups are compared. For linear regression analysis, R
2
 values and ANOVA significance 
values are reported. For western blots, occasional bands were not quantified a priori due 
to smearing or bubble artifacts that would disrupt the accuracy of quantification. For all 




Large pyramidal neurons in the cerebral cortex and hippocampus are selectively 
vulnerable to depletion of TDP-43 
It has long been recognized that certain large pyramidal neurons, including those 
of the hippocampal CA1 and frontal cortex layer V, are selectively vulnerable to 
neurodegeneration in AD
100,101
. To determine whether these neuronal populations are also 
more sensitive to depletion of TDP-43, we employed the tamoxifen-inducible Cre
ER
 
recombinase system to conditionally ablate Tdp-43 in forebrain neurons. Mice with 
floxed Tdp-43 alleles
60
 were crossed with the CaMKIIα-Cre
ER





 (cT) mice (Fig. 1a). Administration of tamoxifen in adult cT 
mice led to depletion of TDP-43 in ~80% and ~30%, respectively, of hippocampal 
pyramidal and layer V frontal cortical neurons (Fig2. a-c).  
 





alleles. Administration of tamoxifen leads to cre-





;APPswe/PS1dE9 mice and littermate controls. (#) indicates the Mendelian frequency of pups 






Figure 2. TDP-43 depletion in the cortex and hippocampus of cT mice. (a,b) TDP-43 (red) with 
hematoxylin counterstain (blue) for representative AP and cTAP sections in the (a) hippocampus 
and (b) cortex. (c) Quantifications of % neurons retaining TDP-43 staining for each genotype. 





Depletion of TDP-43 led to progressive age-dependent forebrain atrophy in the 
hippocampus, cortex, and corpus callosum (Fig. 3a,d). As expected, the volume of the 
cerebellum remained normal (Fig. 3d), since TDP-43 is not depleted in this region. 
Interestingly, we observed early selective vulnerability to depletion of TDP-43 in 
hippocampal CA3/2 (Fig. 3b,e) and cortical Layer V (Fig. 3c,f) neurons. Pathological 
accumulation of phosphorylated neurofilament
110
 was evident in layer V neurons lacking 
TDP-43 as early as 3 months (Fig. 3f,g) and >50% of these neurons degenerated by 4 
months of age (Fig. 3c, graph not shown) [t(10)=7.029, p<0.001, wt (M=868, SD=78), 
cT (M=385, SD=137), n: wt=5, ct=7]. In the hippocampus, 40% of CA3/2 neurons were 
lost by 6 months (Fig. 3e). One interpretation of these findings is that some regions 
vulnerable to depletion of TDP-43 are also vulnerable in human AD (i.e. frontal cortex 
layer V), while others may be distinct (i.e. hippocampus CA3/2 in mouse vs. CA1 in 
human). Another possibility is that the apparent difference in hippocampal selective 
vulnerability is actually due to differences in the distribution of neurons with TDP-43 
nuclear depletion in human AD vs our cT mouse model. While cT mice have depletion of 
TDP-43 in >80% of all hippocampal neurons, human AD brains have depletion of TDP-
43 only in a small subset of neurons, and current evidence suggest they are unevenly 
distributed in throughout the hippocampal layers
111,112
. Further studies are required to 
determine the frequency of TDP-43 depletion in each hippocampal region of AD cases, 





Figure 3. TDP-43 LOF leads to progressive forebrain atrophy and selective vulnerability in 
hippocampal CA3/2 and cortical Layer V neurons. (a-c) Representative cresyl violet stained 
sections. (a) Progressive hippocampal and cortical atrophy in cT mice, with cortical thinning and 
severe CA3/2 cell loss (arrows). (b) Selective degeneration of CA3/2 neurons in cT mice (some 
indicated by arrows) at 4 months, while CA1 and DG are unaffected. (c) Numerous degenerating 
neurons in layer V (arrows) of cT mice at 4 months. (d) Regional volume in cT mice is reduced in 
hippocampus (Hp) [F(1,11)=18.836, ***p=0.001], cortex (Ctx) [F(1,11)=46.435, ***p<0.001], 
and corpus callosum (CC) [Welch(1,5.505)=19.470, **p=0.001], but not cerebellum (Cb) 
[F(1,11)=0.066, p=0.803], compared to wt (wt n=5, ct n=8). (e) CA3/2 neurons are selectively 
lost at 6 months [t(10)=3.428, **p=0.002; wt (M=182.42, SD=54.41), cT (M=104.62, 
SD=11.37)], followed by the dentate gyrus (DG) at 14 months (t(14)=2.339, *p=0.035) while 
CA1 neurons are unchanged [t(14)=1.843, p=0.087]. (3m and 6m n=6; 14m n=8). (f) Pathologic 
accumulation of phosphorylated neurofilament (SMI31, arrows) occurs in layer V neurons in cT 
mice at 3 months (arrows). (g) Co-staining of TDP-43 (yellow) and SMI31 (red) shows neurons 
with neurofilament pathology are depleted of TDP-43 (arrowheads). Scale bars (a)=200 μm 




Figure 3.  
 
 
Depletion of TDP-43 in forebrain neurons accelerates neurodegeneration in 
APPswe/PS1ΔE9 mice 
Previous work has shown that TDP-43 proteinopathy in AD cases correlates 
strongly with worsened cognition compared to AD cases without this pathology
52
. 
However, it remains unclear whether nuclear depletion of TDP-43 accelerates 
neurodegeneration and cognitive decline, or whether it merely occurs alongside these 
deficits. To assess whether nuclear depletion of TDP-43 might accelerate 




 (cT) mice with AD-
linked APPswe/PS1ΔE9 (AP) mice to generate APPswe/PS1ΔE9 mice lacking Tdp-43 in 
forebrain neurons (cTAP) (Fig. 1b). Though APPswe/PS1ΔE9 mice lack frank neuron loss, 
they exhibit significant synaptic and mitochondrial degeneration
87,113
, pathological 
features that are well-suited to assess accelerated neurodegeneration in an AD-related 
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context. As expected, the expression of APPswe/PS1ΔE9 had no additional effect on the 
rate of Tdp-43 excision (Fig. 2c).   
Histological and electron microscopical analysis revealed numerous CA1 
pyramidal neurons with markedly swollen, empty cytoplasm in cTAP mice compared to 
control littermates, suggesting degenerating neurons (Fig. 4; Fig. 5a-c). In addition, some 
cTAP animals also showed occasional darkly stained pyknotic cells within the CA1 layer 
and severe vacuolation of the stratum radiatum (Fig. 4), while these abnormalities were 
absent from cT and AP mice. Accelerated neurodegeneration in cTAP mice was further 
confirmed by morphological analysis, judged by severe swelling and dystrophy in 
mitochondria and Golgi/ER, and cytoplasmic discontinuity with loss of ribosomes (Fig. 
5b,c).  
 
Figure 4. Severe degenerative phenotypes are visible in cTAP mice compared to littermate 
controls. Representative series of H+E stained sections from 5 mice/genotype. Degenerating 
neurons with pale staining cytoplasm (some indicated by arrows) are especially numerous in 
cTAP mice compared to littermate controls at 8 months. In addition, a subset of cTAP mice (#2, 
4+5) display severe vacuolation (*) of the CA1 stratum radiatum (sr) and stratum oriens (so) 






Figure 5. Depletion of TDP-43 accelerates neurodegeneration in APP/PS1 mice. (a) H+E 
staining: numerous CA1 pyramidal neurons show pale staining cytoplasm in 8 month cTAP mice 
(bottom), in contrast to normal cytoplasm of AP (top) and most cT (middle) neurons. Occasional 
darkly stained pyknotic cells are also visible in cTAP mice. Scale bars=100 μm. (b) Electron 
micrographs from CA1 pyramidal neurons at 6 months show sparsely populated and 
discontinuous cytoplasm (yellow) with loss of ribosomes (c, boxed) in cTAP mice, compared to 
cT and AP littermates (n=1 animal/group). Dystrophic organelles, including mitochondria (b, red; 
c, arrows), and Golgi/smooth ER (b, green) are most severe in cTAP mice. Dystrophic neurites 
(pink) only occasionally contain lysosomes (black). Scale bars=2 μm. (d) Mitochondrial Cox1 is 
reduced in cTAP [F(3,26)=3.044, p=0.047, Gabriel *p=0.033], but not AP (Gabriel p=0.462) or 
cT mice (Gabriel p=0.397), compared to wt littermates at 4 months. (wt=9, AP=11, 
cT/cTAP=10). (e) Lysosomal Tecpr1 is reduced in TDP-43 depleted mice compared to AP at 4 
months [F(3,31)=14.322, p<0.001; Games-Howell cT ***p<0.001, cTAP *p=0.017] (wt n=8; 
AP, cT, cTAP n=9). Its autophagosomal binding partner Atg5-12 is also reduced in 8 month 
cTAP mice compared to AP [F(3,20)=11.902, p<0.001; Gabriel ***p<0.001] and cT (Gabriel 
*p=0.016), while another autophagosome protein Atg7 is not [Welch(3,9.619)=1.680, p=0.236]. 
GSK3 is significantly increased in 8 month cTAP [F(3,20)=7.012, p=0.002; Gabriel p=0.006] but 
not AP (p=1.000) or cT (p=0.242) mice compared to wt littermates. (4m: wt n=6, AP n=7, cT 
n=11, cTAP n=10; 8m: wt n=5, AP n=6, cT n=7, cTAP n=6). (f) Synaptophysin (Syp) is reduced 
in 8 month cTAP mice compared to AP [F(3,20)=8.860, p=0.001; Gabriel **p=0.003) and cT 
(Gabriel *p=0.048).  PSD95 and Gphn do not show accelerated changes, though PSD increased 
in all transgenic genotypes [Welch(3,9.648)=40.973, p<0.001; Games-Howell AP ***p<0.001, 
cT **p=0.002, and cTAP **p=0.007] compared to wt at 8 months.  β-tubulin-III is reduced in 8 
month cTAP [F(3,20)=5.640, p=0.006; Gabriel **p=0.007], but not AP (Gabriel p=0.290) or cT 
(Gabriel p=0.952) mice compared to wt. (4m: wt=9, AP=11, cT/cTAP=10; 8m: wt=5; AP=6; 
cT=7, cTAP=6) Outliers (○), and extreme cases (◊).  
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We showed previously that depletion of TDP-43 leads to the incorporation of 
aberrant cryptic exons, and usually subsequent degradation of the associated mRNAs
68
. 
To assess the possible contribution of these cryptic exons to accelerated 
neurodegeneration in cTAP mice, we performed functional pathway analysis on the 
RNAs most likely to be strongly affected by TDP-43 depletion. RNA sequencing data 




 mouse brains and non-transgenic 
littermates (Jeong et al., in review). Genes were selected for functional analysis if the 
cryptic exon was included in at least 50% of the total RNA generated, or if the RNA fold-
change was greater than 1.5.; qualities that make them more likely to exert a meaningful 
effect on neuronal function. The functional categories of these genes were determined by 
a manual literature search (Table 1). Six genes had predominantly developmental 
functions, and three genes had unclear functions and were excluded from the final table. 
These exclusion criteria reduced the list from >100 transcripts to 20. Importantly, we 
identified three pathways strongly implicated in the pathogenesis of AD that are also 







 (Table 1). We examined essential components of these 










Table 1. Functional pathways of selected transcripts containing TDP-43-associated cryptic exons 
that are most likely to exert a functional effect on neurons. The selection procedure is described 
fully in the Methods. Genes are color coded by strength of downregulation (blue) or upregulation 
(red) of their RNA products. Increasing intensity of color indicates a stronger effect. Pathways in 
bold have been strongly implicated in the pathogenesis of AD. 
Synaptic/ 
secretory 







Cacna1b    Mrps6 Tecpr1 Usp15 Crlf1 Brms1l 
Cdh22 Synj2bp      Camk1g  Celf5 
Dlg3            Crem   
Fxyd2      
Kcnmb4      
Pitpnm3         
Ralgps2         
Src                
Rgs17           
Unc13a         
Vps13d         
 
In mitochondria, we observed a significant loss of Cox1, an essential component 
of the electron transport chain, in cTAP mice compared to littermate controls (Fig. 5d). In 
the autophagy pathway, we previously reported that Tecpr1, critical for fusion of 
autophagosomes to lysosomes
117
, is a major target of TDP-43 in the brain (Jeong et al. in 
review). Further, protein levels of Tecpr1 were indeed reduced in mice lacking TDP-43 
(Fig. 5e). Tecpr1 binds the Atg5-12 complex
117,118
, and depletion of Atg5 has been shown 
to cause neurodegeneration in vivo
119
. Notably, Atg5-12 was also reduced in cTAP mice 
compared to littermate controls by 8 months, while another essential autophagosome 
formation factor, Atg7, remained unchanged (Fig. 5e). The apparent specificity of this 
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downregulation suggests that incorporation of some TDP-43-associated cryptic exons 
may impair neuronal function directly. Finally, the pre-synaptic vesicle protein 
synaptophysin was reduced in cTAP mice at 8 months compared to littermate controls 
(Fig. 5f), as was the axonal structural marker β-tubulin-III (Fig. 5f). Post-synaptically, no 
significant differences were found in excitatory (PSD-95) or inhibitory (gephyrin) post-
synaptic scaffolds (Fig. 5f), consistent with observations that presynaptic terminals are 
initially affected in cases of AD
120
. Together, our data suggest that pathways impacted by 
cryptic exon incorporation due to nuclear depletion of TDP-43 contribute to 
neurodegeneration in cases of AD with TDP-43 pathology, and may open the door to new 
therapeutic opportunities.  
Interestingly, active GSK3, a kinase that promotes autophagosome formation
121
, 
was increased in cTAP mice compared to littermate controls (Fig. 5e), though 
autophagosome formation factors themselves were either decreased (Atg5-12) or 
unchanged (Atg7) and no autophagosomal pathology was seen by EM. This apparent 
contradiction may reflect an attempt by TDP-43 depleted neurons to compensate for a 
deficit in autophagy by increasing signaling that promotes this pathway. Notably, 
increased GSK3 activation is well-documented in AD cases
122
, suggesting that this 
finding in cTAP mice warrants further study. Further experimental manipulation of the 
autophagy pathway in neurons with nuclear depletion of TDP-43 will help unravel its 
consequences on autophagy and may shed light on important mechanisms of AD 
pathogenesis.  
Though our data would seem to suggest that mitochondrial degeneration occurs 
first in cTAP mice at 4 months, followed by defects in autophagy and synaptic signaling 
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by 8 months, the complexities of the latter pathways do not allow us to make strong 
conclusions about the timeline of degenerative processes. For example, compensatory 
axon sprouting has been shown in mice carrying AD-linked mutations
123,124
 that could 
mask degeneration of synaptic terminals. Therefore, future detailed studies would be of 
interest to establish the order, or simultaneous onset, of degenerative mechanisms due to 
TDP-43 depletion in AD, and may provide useful information for the development of 
therapeutics and our understanding of AD pathogenesis. 
 
Accelerated neurodegeneration in APPswe/PS1ΔE9 mice with depletion of TDP-43 is 
independent of the Aβ plaque burden 
Unexpectedly, while depletion of TDP-43 in APPswe/PS1ΔE9 mice accelerated 
neurodegeneration, it also significantly reduced Aβ plaque burden (Fig. 6a,b). In addition, 
the relative level of fibril vs. pre-fibril oligomers was also significantly reduced in 
forebrain homogenates of cTAP compared to AP mice (Fig. 6c,d). These data indicate 
that the accelerated neurodegeneration occurring in cTAP mice is independent of the Aβ 
plaque burden or fibrillar Aβ oligomers. Importantly, the total levels of Aβ42 were 
unchanged in the forebrains of cTAP mice compared to littermate controls (Fig. 7a). 
Simple linear regression for dependence modeling of a variable demonstrated that the 
reduced plaque density was also not significantly explained by volume loss (Fig. 7b). 
Finally, the levels of the Aβ precursor protein (APP) and the proteases that cleave it, PS1 
and BACE1, were all unchanged in cTAP mice compared to AP littermates. These 
findings indicate that the reduced burden of fibrillar and plaque Aβ is not due to simple 
changes in Aβ production, and may reflect an important mechanistic effect of TDP-43 
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depletion on Aβ dynamics and other neuronal functions. Future experiments would be of 
great interest to uncover whether depletion of TDP-43 might alter processes like Aβ 
fibrilization, secretion, or degradation. In addition, experimentally depleting TDP-43 in 
the brain after Aβ plaque deposition has already begun would provide further information 
on the processes underlying Aβ plaque reduction in the current cTAP mouse model. 
 
 
Figure 6. Accelerated neurodegeneration in cTAP mice is independent of Aβ plaques and fibrillar 
oligomers. (a) Representative series of 4G8 stained plaques (arrow, example) in 5 different 
animals/genotype at 8 months. The reduction in plaque burden in cTAP (bottom) compared to AP 
(top) mice is obvious by visual inspection. Scale bars=200 μm. (b) Plaque burden is significantly 
reduced in the forebrains of cTAP mice compared to AP littermates at 4 months [F(1,16)=10.756, 
**p=0.005] and 8 months [F(1,18)=30.329, ***p<0.001].  (3m,4m n=9/group; 8m AP=9, 
cTAP=11). Outlier (○). (c) Representative dot blots of pre-fibril (A11) and fibril (OC) oligomers 
soluble in PBS after centrifuging at 100,00xg. (d) Relative levels of fibrillar oligomers (OC:A11) 
were significantly decreased in cTAP mice at 4 months [F(1,10)=6.626, *p=0.028] (n=6). 







Together, our findings support a model whereby nuclear depletion of TDP-43 
contributes to the pathogenesis of AD. This provides strong rationale to develop novel 
therapeutics to alleviate the depletion of nuclear TDP-43 and to create functional ante-
mortem biomarkers for early detection. Additionally, our data are consistent with the 
view that non-fibrillar soluble forms of Aβ, rather than fibrils and plaques, facilitate 
neurodegeneration in AD
9,88
. Given the apparent importance of the conformational state 
of Aβ, the equilibrium relationship between different conformational states underscores a 
great challenge of designing effective of Aβ-directed therapeutics
125
. However, interim 
data from recent clinical trials showing that Aβ-directed antibodies derived from aged 
cognitively normal humans, such as Aducanumab (BIIB037, clinialtrials.gov), reduce 
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brain Aβ and halt cognitive decline indicate that harnessing the immune system may 
allow clinicians to safely lower multiple forms of Aβ simultaneously (presented at the 
12
th
 International AD/PD Conference, Nice, France, March 2015). Since nuclear 
depletion of TDP-43 may occur in a majority of AD cases
52
, our findings suggest that 
stratifying AD subjects with TDP-43 pathology may greatly empower trials of promising 
Aβ-directed therapeutics. 
 
Figure 7. Reduced plaque burden is not explained by volume loss or lack of Aβ production. (a) 
Levels of Aβ42 were not changed in the forebrain of cTAP mice at 4 months 
[Welch(1,18.987)=2.584, p=0.124] (AP=11, cTAP=10). (b) Scatter plot of plaque area fraction 
vs. volume in the forebrain. Linear regression analysis revealed that volume loss does not 
contribute significantly to plaque area fraction (R
2
=0.106; ANOVA F(1,29)=3.425, p=0.074; 
n=31). (c) Levels of the Aβ precursor protein (APP) and the proteases that cleave it, PS1 and 
BACE1, are all unchanged in cTAP compared to AP littermates. APP [F(1,11)=0.164, p=0.694] 







Together, our data support the hypothesis that depletion of TDP-43 contributes to 
the pathogenesis of AD in cases with TDP-43 proteinopathy. Previous work has 
established an essential role for TDP-43 in mammalian embryogenesis (Kraemer et al., 
2010; Sephton et al., 2010) and vertebrate development (Schmid et al., 2013), as well as 
diverse roles during adulthood (Chiang et al., 2010) including neuron survival in the 
spinal cord (Wu et al., 2012; Iguchi et al., 2013; Yang et al., 2014). Importantly, we now 
show that in adult mice, depletion of TDP-43 is not equally toxic to all populations of 
neurons, as the frontal cortex layer V and hippocampal CA3/2 pyramidal neurons are 
selectively vulnerable to TDP-43 depletion in the forebrain, even compared to other large 
pyramidal neurons like those of the CA1.  As we noted previously, further studies are 
required to determine whether the same pattern of selective vulnerability occurs in AD 
patients with TDP-43 proteinopathy. However, data from AD patients in general has 
shown that frontal cortex layer V neurons are indeed selectively vulnerable in the disease 
generally
100,101
. In the hippocampus, most data from AD cases (not stratified by TDP-43 
proteinopathy) indicate that the CA1 is most vulnerable
126
. Re-examination of these 
datasets with stratification for TDP-43 proteinopathy would be of great interest, 
particularly datasets using histology with unbiased stereology that provide greater 
sensitivity than volumetric studies. However, the design and interpretation of these 
studies may be complicated by the fact that TDP-43 proteinopathy occurs only in a small 
subset of neurons that appear unequally distributed throughout hippocampal sub-regions 
(Uryu et al., 2008; Kadokura et al., 2009). Nevertheless, if depletion of TDP-43 does 
cause selective vulnerability in the CA3/2 in humans, AD cases with TDP-43 
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proteinopathy would have two populations of severely dysfunctional hippocampal 
neurons, which may contribute to the worsened cognition observed in these patients
52
.  
Second, we show that depletion of TDP-43 accelerates hippocampal 
neurodegeneration, while reducing Aβ fibrils and plaques in APPswe/PS1dE9 mice. Our 
data suggest that TDP-43 may accelerate neurodegeneration both directly, through 
incorporation of cryptic exons, and indirectly, by increasing non-fibril Aβ oligomers. 
Specifically, in the autophagy pathway we show that an autophagosome formation factor 
(Atg5-12) that is a binding partner of a downregulated TDP-43-associated cryptic exon 
target (Tecpr1) is also downregulated, while an unrelated autophagosome formation 
factor (Atg7) is not. However, further studies are required to rigorously evaluate the 
mechanisms by which depletion of TDP-43 contributes to AD. For instance, rescuing 
suppression of TDP-43 associated cryptic exons in cTAP mice and examining the 
degenerative phenotypes that can be prevented or rescued would test the hypothesis that 
failure to repress cryptic exons directly contributes to neurodegeneration. To that end, our 
group has developed a fusion protein coupling the RNA-binding domains of TDP-43 with 
the splicing repressor region of the RAVER1 protein, and have shown that it can suppress 
TDP-43-associated cryptic exons
68
. We can, therefore, use this construct to evaluate the 
contribution of cryptic exon suppression to the deficits observed with depletion of TDP-
43.  
Another important factor to consider in studying TDP-43-associated cryptic exons 
is that they are nonconserved, meaning that the genes containing cryptic exons vary 
between species
68
. Therefore, the genes affected by depletion of TDP-43 in our mouse 
model will have little to no overlap with those affected in human AD. Currently, our 
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group is working to uncover the cryptic exon targets of TDP-43 depletion in human 
neurons, which will allow a direct comparison of both the target genes and the pathways 
to which they belong. Therefore, although the specific genes will likely differ between 
mouse and human, the pathways they disrupt may overlap. Indeed, the original studies of 
the role of TDP-43 in splicing found that the incidence UG dinucleotide repeats to which 
TDP-43 binds increased with the length of introns
61
, suggesting that UG repeats occur in 
a random manner throughout the genome. Therefore, pathways which are most crucial to 
neurons, and have the most genes associated with them, are also most likely to have an 
abundance of cryptic exons in any species. In this manner, the general mechanism by 
which depletion of TDP-43 contributes to AD may be conserved in mouse, although the 
particular gene targets are not conserved. 
Whether the contributions of Aβ and depletion of TDP-43 are independent (acting 
on different pathways), synergistic (acting on the same pathways), or epistatic (one leads 
to the other) is highly relevant for development of therapeutic strategies. If the two 
contribute to neurodegeneration through a common mechanism, one therapeutic agent 
may be sufficient to halt or slow neurodegeneration in AD patients with multiple 
pathologies. However, our data suggest that TDP-43 may accelerate neurodegeneration 
through mechanisms that are at least partially independent of Aβ (though further studies 
are required to firmly establish this hypothesis). In addition, a recent clinico-pathologic 
study of aged individuals with and without dementia showed that the presence of one 
pathology (TDP-43 proteinopathy or Aβ plaques) did not make the other more likely to 
occur
47
. This suggests that Aβ- and TDP-43 dysfunction are likely not epistatic of each 
other. Importantly, if these dysfunctions represent separate mechanistic pathways, the 
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administration of therapies directed to either alone would be expected to produce minimal 
benefits in AD patients with TDP-43 proteinopathy. Given that up to 60% of AD cases 
have TDP-43 proteinopathy, we hypothesize that this situation may confound the 
evaluation of current Aβ-directed therapeutics, and that stratifying subjects with TDP-43 
pathology could empower AD clinical trials. 
As discussed previously, our data in cTAP mice suggest that Aβ and depletion of 
TDP-43 synergistically contribute to neurodegeneration in AD. However, we cannot rule 
out the possibility that another factor related to the AD-linked mutations, such as altered 
PSEN1 function, may be contributing to accelerated neurodegeneration in cTAP mice. To 
rigorously demonstrate that Aβ is indeed the key interactor, experiments are required to 
remove the Aβ from mice with familial AD mutations, for instance using anti-Aβ 
antibodies. If Aβ is the true catalytic factor then the degenerative differences 
demonstrated here between cT and cTAP mice should not be present in cTAP mice 
treated with Aβ antibodies from an early age. Currently available human-derived Aβ 
antibodies, such as Aducanumab
127
, which are currently in clinical trials, provide a 
therapeutically relevant choice for these experiments.  
Our study is an important step in investigating the multiple mechanisms that may 
contribute to sporadic AD, which will aid the development of effective therapeutics. 
However, therapeutic success will depend heavily on our understanding of disease 
mechanisms and on the rigor of pre-clinical investigations. The recent failures of the γ-
secretase inhibitor semagacestat were a strong reminder of the dangers of rushing to 
clinical trial, as the drug worsened cognition in AD patients instead of improving it, and 





Since Notch-related adverse events also occur in mice with inactivation of γ-secretase
129–
131
, and subsequent evidence has shown that semagacestat preferentially inactivates 
Notch over APP
132
, more careful preclinical evaluation should have prevented this 
unfortunate failure. However, despite this recent reminder, another drug, bexarotene, is 





, Appendix A), to consistently replicate the benefits reported in the initial 
study
137
. In addition to the potential damage to patients, clinical trials are expensive and 
time-consuming, and testing a drug that preclinical data indicates is likely to fail wastes 
limited resources. Additionally, failure of an ill-chosen drug makes it more difficult for 
other, potentially effective drugs of the same class to gain approval, as is now the case 
with γ-secretase inhibitors in general due to the failure of semagacestat in particular
138
.  
Our work provides strong rationale to develop novel therapeutics to alleviate the 
depletion of TDP-43 and to create functional ante-mortem biomarkers for early detection. 
Rescue of TDP-43-associated cryptic exon suppression may represent a viable 
therapeutic option for AD and other neurodegenerative diseases with TDP-43 
proteinopathy, and we have begun preclinical evaluation of this hypothesis. As we 
discuss above, one important step in this evaluation includes experiments that establish 
the contribution of cryptic exon suppression to TDP-43 depletion-related 
neurodegeneration. The effects of cytoplasmic TDP-43 aggregation may also be relevant 
to disease and should be investigated. Finally, the mechanisms by which TDP-43 and Aβ 
may interact to cause neurodegeneration will be highly relevant, and will require 
carefully designed studies, as discussed previously. Together, these and other approaches 
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will increase our knowledge of AD pathogenic mechanisms, and aid the rational 
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Background: Though the precise cause(s) of Alzheimer's disease (AD) remain unknown, 
there is strong evidence that decreased clearance of β-amyloid (Aβ) from the brain can 
contribute to the disease. Therapeutic strategies to promote natural Aβ clearance 
mechanisms, such as the protein apolipoprotein-E (APOE), hold promise for the 
treatment of AD. The amount of APOE in the brain is regulated by nuclear receptors 
including retinoid X receptors (RXRs). Drugs that activate RXRs, including bexarotene, 
can increase APOE and ABCA1 production, and have been shown to decrease the Aβ 
burden and improve cognition in mouse models of Aβ amyloidosis. Although recent 
bexarotene studies failed to replicate the rapid clearance of Aβ from brains, behavioral 
and cognitive effects of this compound remain controversial.   
40 
 
Findings: In efforts to clarify these behavioral findings, mutant APP/PS1 mice were 
acutely dosed with bexarotene. While ABCA1 was upregulated in mutant APP/PS1 mice 
treated with bexarotene, this drug failed to attenuate Aβ plaques or cognitive deficits in 
these mice.  
Conclusions: We recommend rigorous preclinical study to evaluate the mechanism and 
utility of such a compound for AD therapy. 
 




The principle pathological characteristics of Alzheimer’s disease (AD) include the 
extracellular deposition of β-amyloid (Aβ) plaques and intracellular aggregation of tau in 
the brain, abnormal synaptic function, and chronic inflammatory responses in neural 
tissue. A well-studied mouse model of Aβ amyloidosis is the double transgenic 
APPswe/PS1ΔE9 mouse that exhibits Aβ plaques in the hippocampus and cortex beginning 
at 6 months of age (1). The progression of Aβ deposition occurs more rapidly in these 
transgenic females than in males (2). While Aβ has a clear link to AD – either directly or 
through the processing mechanisms of its precursor protein APP – Aβ is also present in 
healthy individuals in the form of low molecular weight soluble Aβ peptides that likely 
serve physiological roles (3). Levels of Aβ peptides are managed by clearance 
mechanisms in the brain that activate microglia to facilitate the removal of Aβ from the 
extracellular space (4). The most prominent of these clearance components is the 
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cholesterol transporter apolipoprotein-E (ApoE) because the E4 allele as compared to that 
of E2 or E3 is the most significant risk factor for the development of non-familial 
(sporadic) AD. Individuals with APOE4 have a pronounced increase in Aβ 
oligomerization (5) and AD incidence (6,7) relative to carriers of the other APOE alleles. 
APOE4 has also been found to have decreased affinity for Aβ compared to APOE3 or 
APOE2, but only when activated by lipidation (8), which implies that dysfunction in the 
regulation and action of APOE isoforms can play contributing roles in the pathogenesis 
of AD. The convergence of this data indicates that promoting APOE may be a productive 
therapeutic strategy in AD.  
The transcription of APOE is facilitated by activation and heterodimerization of 
the nuclear receptor retinoid X receptor (RXR) with its partner receptors peroxisome 
activated receptors (PPARγ) or liver X receptors (LXR). These nuclear receptors also 
activate lipidators such as ABCA1 (9, 10), which appear necessary for the Aβ clearing 
abilities of ApoE (8, 11, 12). Therefore, a number of RXR agonists have been tested as a 
potential therapeutic mechanism of increasing Aβ clearance through ApoE. Bexarotene is 
one such agonist, which is selective for RXR and is FDA-approved for the treatment of 
cutaneous T-cell lymphoma. Cramer et al. (13) conducted studies with bexarotene in 
transgenic mouse models of Aβ amyloidosis. They reported that acute treatment with 
bexarotene upregulated ABCA1 and ApoE, rapidly reduced the Aβ plaque burden in the 
brain, and ameliorated cognitive deficits in these models. However, several groups have 
failed to replicate the effect of bexarotene on Aβ plaque burden in these and other related 
mouse models, despite achieving upregulation of the proposed targets ApoE and ABCA1 
(14,15,16,17). While the original experiments were conducted on mouse models (Tg2576 
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and APPswe/PS1ΔE9) that exhibit significant gender-related pathological differences (18 
and 2, respectively), no distinction of gender was made in their analysis (13).  In using a 
small cohort of mice in the studies, these gender differences could skew treatment groups 
leading to a false positive treatment effect. Moreover, gender-related differences are 
important in the evaluation of any RXR agonist or other compounds influencing this 
pathway because ApoE function can be modified by gender (19,20).  
In this study, we attempted to clarify this gender discrepancy by measuring brain 
Aβ plaque load in male and female cohorts of APPswe/PS1ΔE9 mice acutely dosed with 
bexarotene. We used two different formulations of bexarotene, one in DMSO (as used by 
Cramer et al. (13)) and one in corn oil to assess any potential issues with DMSO toxicity. 
Since RXR and LXR agonists have been shown to modulate microglial activity to 
dampen their inflammatory responses and enhance their clearance abilities (21), we also 
examined microglial activation in these treated mice. Finally, no study has yet replicated 
the effect of bexarotene on fear memory, and its cognitive effects remain controversial. 
Therefore, we evaluated the effect of bexarotene on context-dependent and conditioned-
stimulus-dependent fear memory.  
Results 
To confirm the apparent benefit of acute treatment with bexarotene (13), we 
initially dosed two cohorts of 8 month old female APPswe/PS1ΔE9 mice with 100 mg/kg of 
this RXR agonist (or indicated vehicle) by daily oral gavage. We analyzed the effects of 
treatment on ABCA1 levels in APPswe/PS1ΔE9 mice, and found that the use of DMSO or 
corn oil as a vehicle does not create a significant difference in the relative means of 
bexarotene treated groups normalized to their respective vehicle [(M=1.570, SD=0.203) 
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and (M=1.641, SD=0.157), respectively F(1,10)=0.044, p=0.837], and that there was no 
interaction between vehicle used and treatment group. As expected, we found that 
bexarotene significantly increased levels of ABCA1 by 50% after three days of treatment 
(Fig.1A) [* F(1,13)=5.261, p=0.027], confirming that this compound engaged the 
expected targets in the brains of these mice. To assess the impact of bexarotene on 
amyloid burden in male and female mice, we dosed an 8 month (DMSO vehicle) and an 
11 month old (corn oil vehicle) cohort of APPswe/PS1ΔE9 mice.  Again, we found no 
significant effect of vehicle type on Aβ levels [cortex F(1,29)=0.277, p=0.965, 
hippocampus F(1,29)=3.266, p=0.081], and no interaction between vehicle used and 
treatment group. In contrast to findings of Cramer et al. (13), no significant differences in 
Aβ plaque burden were observed in brains of bexarotene treated APPswe/PS1ΔE9 mice 
compared to vehicle [cortex F(1,29)=0.002, p=0.965, hippocampus F(1,29)=0.398, 
p=0.533] (Fig. 1B). Though the sample sizes for each group are small, sample size 
estimates for each experiment showed that they each have a power ≥88%. In addition, the 
inability of bexarotene to alter plaque levels in this model has recently been reported by 
additional groups (14,15,16,17). While there has been increasing evidence that plaques 
may not be as informative correlates of disease as soluble forms of Aβ, the inability of 
bexarotene to alter soluble Aβ levels in this mouse model has also been recently reported 
(14,15,16,17). Notably, we observed a significant main effect of gender on plaque levels 
in 11 month old mice. Male groups had significantly lower plaque load compared to 
female groups [* cortex, F(1,19)=20.177, p<0.0005 and ** hippocampus 
F(1,19)=14.045, p=0.001] (Fig. 1C). In 8 month old mice, males were not tested, so that 
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age group could not be included in the analysis for a gender effect, but gender differences 
in plaque load have been reported as early as six months of age in this mouse model (18). 
Analysis of microglial immunoreactivity using an antisera specific to ionized calcium 
binding adaptor molecule 1 (Iba1), a microglial inflammatory and phagocytic marker 
(22), revealed a similar pattern between APPswe/PS1ΔE9 mice treated with bexarotene or 
vehicle (Fig. 2). Despite the potential of RXR agonists to modulate the microglial 
activation present in APPswe/PS1ΔE9 mice, no significant effect of bexarotene was 
observed compared with vehicle administration [cortex F(1,27)=2.231, p=0.147, and 
hippocampus F(1,27)=2.127, p=0.156] (Fig. 2A). No significant main effect of gender 
was found, and no interaction was detected between gender and treatment. Microglial 
morphology was also analyzed, as described in (23). Microglia in transgenic female (Fig. 
2B) and male (Fig. 2D) animals show a transitional amoeboid (activating) morphology 
with clustering of these activated microglia, which was unchanged after administration of 
bexarotene (Fig. 2C and E, respectively). In contrast, microglia from female and male 
non-transgenic animals have a uniformly ramified, resting morphology as shown in 
Additional File 1. A recent study analyzing the presence of Aβ in Iba1-positive microglia 
also failed to show an effect of bexarotene on Aβ uptake and clearance (17).Finally, we 
analyzed the effects of bexarotene treatment on context-dependent freezing behavior in 8 
month old female APPswe/PS1ΔE9 and littermate non-transgenic mice according to the 
protocol described by Cramer et al. (13). Behavioral measures in males and females were 
assessed separately due to gender differences present in this mouse model (18). In the 
training session, APPswe/PS1ΔE9 receiving vehicle and bexarotene treatment demonstrated 





p=1.000, male tg p=0.182, female nontg, female tg p=1.000]  (see Fig. 3A) indicating 
that acquisition of fear response was not significantly affected by genotype, sex, or 
treatment.  
Testing for context-dependent fear memory yielded no significant differences 
among any of the groups [F(7,44)=1.794, p=0.113]. This finding was not surprising 
given the strong unconditioned stimulus and its multiple presentations in the protocol 
described in (13), which was used here for replication purposes. Of particular note, the 
group means for context-dependent freezing behavior in Fig. 3A were almost double 
those reported in Cramer et al. (13) using these testing parameters. We also performed a 
high-sensitivity alternative conditioning paradigm, consisting of a short pre-exposure 
period and a single delivery of the unconditioned stimulus as described in (24) and the 
Methods. Using this paradigm we detected a significant freezing deficit in 8 month old 
APPswe/PS1ΔE9 females compared to non-transgenic littermates [F(1,17)=5.943, p=0.026] 
(Fig. 4). However, this deficit was not persistent at 10 months of age [F(1,18)=2.824, 
p=0.110] with an opposing trend of increased freezing in APPswe/PS1ΔE9 females (Fig. 4). 
These data indicate that freezing behavior might not be robust or reliable measure of 
cognitive deficits in this mouse model.  
We also analyzed conditioned stimulus (CS)-dependent fear responses, and found 
no effect of bexarotene on freezing behavior in APPswe/PS1ΔE9 mice compared to non-
transgenic littermates (Fig. 3B). However, we again observed an unexplained trend of 
freezing deficit in non-transgenic males treated with bexarotene as compared to vehicle- 
and bexarotene-treated APPswe/PS1ΔE9 males (Fig 3B).  In addition, a significant gender 
difference was also detected in this task between males and females of vehicle-treated 
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non-transgenic and APPswe/PS1ΔE9 animals [main effect of gender F(1,15)=23.506, 
p<0.0005; main effect of genotype F(1,15)=1.898, p=0.189, no significant interaction] 
with females [M=42.006,SD=17.65] showing lower levels of freezing than males 
[M=76.260,SD=10.50] (Fig. 3B). These gender-related differences were no longer 
observed in mice treated with bexarotene [males M=48.79, SD=20.71, females M=54.55, 
SD=21.48; main effect of sex F(1,27)=0.630, p=0.434; main effect of genotype 
F(1,27)=1.388, p=0.249; no significant interaction. The condition of equality of variances 
was not met for this test].  
 
Table 1. Summary of recently published findings on bexarotene in mouse models of Aβ 
amyloidosis related to the study presented here (first row). N/A indicates that the listed data point 







Our data failed to replicate the apparent benefit of acute bexarotene treatment in 
mouse models of Aβ amyloidosis previously reported (13). It is unknown whether 
chronic administration of bexarotene or alternate dosing strategies would have a 
beneficial effect. Nevertheless, our failure to replicate the initial observations emphasizes 
the importance of gender-related differences in the APPswe/PS1ΔE9 mouse model, and 
other work indicates that these differences may extend to humans (19,20). Since the 
completion of this study, bexarotene has been tested in other animal models of Aβ 
amyloidosis, including APP/PS1-21 (17), 5XFAD (17), and APPswe/PS1ΔE9 with 
APOE3/4 allele knock-in (14), as summarized in Table 1. All have failed to replicate a 
change in soluble or plaque forms of Aβ, with the exception of the non-pathogenic 
soluble Aβ40 species, which decreased after acute treatment with bexarotene in the 
5XFAD mouse model, but not in the APPswe/PS1ΔE9 or the APP/PS1-21 models (17).  
Importantly, we are unable to replicate a robust and persistent fear conditioning 
deficit in the APPswe/PS1ΔE9 mouse model, even with an alternate, highly sensitive testing 
paradigm (24). Fear conditioning is the sole behavioral measure previously used to test 
bexarotene in this model (13). In APPswe/PS1ΔE9 mice with APOE3/4 knock-in, 
bexarotene was reported to rescue deficits in the Radial Arm Water Maze at 7 months of 
age (14), but this testing was also performed on mixed gender cohorts of n=5 per group, 
introducing a potential false-positive treatment effect. Therefore, the current cognitive 
preclinical data do not validate the potential of this drug for Alzheimer’s therapy. 
Together, the array of published work on the effect of bexarotene on pathology 
and cognitive impairment in mouse models of Aβ amyloidosis produces no rigorous 
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evidence that bexarotene is a suitable candidate for the treatment of Alzheimer’s disease 
in patients (Table 1). There are potential discrepancies in the formulation of bexarotene 
used in replicating studies as compared to the original experiments (13,16) due to lack of 
availability of this formulation to other research groups. While the consistent 
upregulation of ABCA1 and ApoE using various formulations of bexarotene 
(13,14,15,16,17) indicates that it does indeed activate the proposed targets, these may not 
be the true mechanism of action responsible for the changes observed in Cramer et al. 
(13). In light of our and other groups (14,15,16,17) overall failures to replicate the key 
findings on bexarotene in mouse models of Aβ amyloidosis, we recommend that the 
original formulation be made available for rigorous preclinical studies in multiple mouse 
models in order to clarify the existing discrepancies and to elucidate the mechanism of 
action before clinical testing progresses. 
Methods 
Animals. APPswe/PS1ΔE9 (B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax) were used. 8 
month and 11 month old APPswe/PS1ΔE9 mice were housed on a 14hr dark:10hr light 
cycle in standard cages with 2-5 mice each and given free access to food and water. 
Bexarotene (ChemieTek) was dissolved in a vehicle of <15% DMSO in milk or in corn 
oil, as indicated in the corresponding figure legends. Mice were weighed at the beginning 
of the treatment period and the necessary volume of solubilized bexarotene was 
calculated to produce a concentration of 100mg/kg for each animal. Animals were 
gavaged with vehicle or bexarotene solution daily for 3, 7, or 14 days, as indicated. 
Studies were performed on mixed gender or females only, where indicated. 
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Brain ABCA1 quantification. Mice were sacrificed two hours after the day three gavage 
using brief CO2 exposure, followed immediately by decapitation. Brains were removed 
and one hemisphere was collected for ABCA1 quantification. Cortices were quickly 
dissected on ice with cold forceps. Samples were placed on dry ice in labeled, pre-cooled 
microfuge tubes. Samples were frozen at -80°C until use. Fresh, cold RIPA buffer (10x 
volume of sample) with Protease Inhibitor Cocktail was added to samples on ice and 
tissue was mechanically dissociated using 1mL pipet tips. Samples were sonicated with 
brief pulses on ice, and centrifuged at 14000rpm for 25 min at 4°C. Supernatants were 
transferred to new labeled microfuge tubes and kept on ice during protein estimation, or 
stored at -80°C until use. Protein concentration was estimated using the BCA Assay, and 
analyzed by the Epoch Com6 spectrophotometer (BioTek) with Gen5 analysis software. 
Samples for protein blot were prepared containing 1.0-1.5μg protein/μL of sample 
solution. Samples were mixed, heated at 70°C for five minutes, then cooled and a volume 
containing 30μg of protein was loaded into wells of 4-12% Bis-Tris gels (Novex) with 
MOPS running buffer. Gel was run for 120 min at 120 volts, then transferred to a PVDF 
membrane for 150 min at 30v. Membranes were probed with ABCA1 mouse monoclonal 
antibody and with antisera against β-tubulin III as a loading control, and were incubated 
with HRP-conjugated secondary antibodies and exposed to HRP substrate. Exposed films 
were scanned without any background- or noise-subtraction and analyzed using ImageJ 
software. The relative optical density of each band was calculated using the area under 
the curve of lane profile plots on unaltered images. The experiment was replicated in 
triplicate, and the mean optical density (OD) was calculated.  
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Aβ Plaque Quantification. Mice were gavaged with 100mg/kg bexarotene for 14 days 
and sacrificed as described above, and hemispheres were immediately immersed in 4% 
paraformaldehyde for 24 hours at 4°C. Brains were then moved to PBS solution for 24 
hours at 4°C, followed by another change of PBS for storage until use. The tissue was 
then embedded in paraffin and sectioned into 10μm coronal slices (7B6-stained) or 10μm 
sagittal slices between 1.2 and 1.5mm from the midline (ubiquitin-stained). Sections were 
mounted onto slides and stained with ubiquitin (Dako) or 7B6 antibodies (Abcam) to 
detect Aβ plaques. Plaque area was calculated using the Area Fraction Fractionator probe 
in the Stereo Investigator stereology program. The counting frame was 150x150 with 
gridsizes 500x500 µm for cortex and 300x300 µm for hippocampus, and a grid spacing 
of 10 µm. Plaque area for hippocampus and cortex were measured and normalized to the 
total area of the brain region for each animal. Data was collected and verified by two 
independent investigators, blinded to groups. 
Iba-1 Quantification and morphological analysis. Animals were sacrificed after 14 
days of gavage and their tissues perfused. The brain tissue of each of the animals was 
removed and placed in a 30% sucrose preservative, and sectioned to a thickness of 40μm 
on a freezing microtome. Every eighth section was immunostained with anti-Iba1 
antibody (1:1000, Wako, cat. #019-19741). Morphology of resting (ramified) and active 
(amoeboid) microglia was analyzed according to the guidelines specified in (23). Briefly, 
ramified microglia are identified with a small cell body and long, thin projections with 
distal branching. In contrast, active microglia exhibit a shortening of projections and 
enlargement of the cell body as they are reabsorbed, leading to an amoeboid morphology.  
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Fear Conditioning. All mice used for these studies were generated by breeding a single 
cohort of 10 male and 20 female mice from the line described above. Animals were 
gavaged with vehicle or bexarotene (100mg/kg) solution daily for 7 days. Behavioral 
tests were performed in the morning before the daily gavage to minimize any effect of 
stress from this procedure on behavior. Three days before the start of the test period, 
animals were handled and the tails marked with permanent marker to eliminate stress 
caused by checking ear-tags just prior to behavioral testing. The following two days 
before behavioral testing, each animal was handled and separately habituated to empty 
waiting cages in a separate room adjacent to the testing room for ten minutes.  
Protocol 1:  
Context- and Cue-dependent fear conditioning was conducted as described in Cramer et 
al (13), beginning after 4 days of gavage (before the 5th administration). Conditioning 
was performed in a test chamber with a shock grid floor and a contextual striped and 
checkered pattern on three of the walls. Testing and data collection were automated by 
ANY-Maze 4.70 software (Stoelting Co., Wood Dale, IL) according to the following 
protocol parameters: Light in the chamber 1.5 visible + 1.5 Infrared, Fan ON (65 dB), 
smell 30% Ethanol, Freezing ON Threshold = 25 msec, Freezing OFF Threshold = 30 
msec, Minimum Freezing Duration = 500 msec.  
Training Session: Mice were placed in empty waiting cages for ten minutes prior to the 
start of the test, then placed in the test chamber and allowed to explore for 120 seconds. 
Mice were then exposed to a conditioned stimulus (CS, 83dB and 2800Hz) for 30 
seconds, followed by a 2 second delay, and finally the unconditioned stimulus (US, 0.6 
mA) for two seconds. Mice remained in the chamber for an additional 30 seconds to 
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measure immediate freezing response following the CS/US pairing. This sequence was 
repeated four times for each animal.  
Context dependent freezing: Context-dependent fear behavior was analyzed 24 hours 
later. Mice were placed in the same test chamber for five minutes without any CS or US 
administration, and freezing behavior was measured throughout the test.  
Conditioned Stimulus (CS)-dependent freezing: An additional 24 hours later, mice were 
tested for CS-dependent freezing behavior. Mice were placed in a novel test chamber 
with plain white walls on all sides and a solid floor. Bedding was placed in the bottom of 
this new chamber, as well as a small paper towel with 1:100 dilution of vanilla extract 
(McCormick) in water. Mice were allowed to explore the chamber for 120 seconds, 
followed by CS presentation for 30 seconds, and a 30 second delay to measure immediate 
freezing response. This sequence was repeated four times for each animal. 
Protocol 2: 
A high-sensitivity context-dependent fear conditioning protocol (modified from 24) was 
also tested in separate cohorts of APPswe/PS1ΔE9 female mice at 5, 8 and 10 months of 
age. Mice were habituated in the same manner as described previously. The test chamber 
was identical, with the addition of a scent cue (coconut extract 1:500 in water, 
McCormick) placed underneath the grid floor. In the Training Session, mice were placed 
in the test chamber and allowed to explore for 30 seconds. Mice were then exposed to the 
same unconditioned stimulus as in the previous paradigm (US, 0.6 mA) for two seconds. 
Mice remained in the chamber for an additional 35 seconds to measure immediate 
freezing response. 24 hours later, mice were placed in the same test chamber for four 
minutes without US administration, and time freezing was measured.   
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Statistical Analysis. Data were analyzed with Univariate Analysis of Variance 
(ANOVA) using SPSS Statistics 20 software. For Fig. 1, analysis was performed on data 
in 2x2 (treatment x vehicle or treatment x sex) between-subjects factorial design. For Fig. 
2, 3 and 4, analysis was performed in a 2x2 (genotype x sex) between-subjects factorial 
design for each treatment group, or a 2x2x2 (genotype x sex x treatment) between-
subjects factorial design, and main effects and interactions were analyzed. Homogeneity 
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Figure 1. Bexarotene significantly increases ABCA1 in the brains of APPswe/PS1ΔE9  mice, but 
does not alter Aβ plaques. (A) Representative Western blot (Vehicle (-), Bexarotene (+)) of 
ABCA1 in cortex of 8.5 mo. female mice, and graph of quantification normalized to β-tubulin-III. 
Bexarotene significantly increases ABCA1 expression by 50% after three days of gavage 
treatment [* F(1,13)=5.261, p=0.027]. (B) Percent brain area covered by plaques in 8 month 
(ubiquitin) and 11 month (7B6) female mice, calculated by stereological estimation on sections 
stained with the antibodies indicated. No significant differences in plaque burden were detected 
between treatment groups. N-values: Ubiquitin – veh=4, bex=6; 7B6 – veh=3, bex=5. Error bars 
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represent standard deviation. (C) Gender comparison between % plaque area in 11 mo. mice, 
calculated by stereological estimation on sections stained with 7B6 antibody. Males had 
significantly lower plaque load compared to females in both treatment groups [* cortex, 
F(1,19)=20.177, p<0.0005 and ** hippocampus F(1,19)=14.045, p=0.001]. Error bars represent 
standard deviation. N-values: females- veh=3, bex5; males- veh=7, bex=8. Sample size estimates 
show this experiment has power of 88%. Representative images of plaques in APPswe/PS1ΔE9 
mice, stained with 7B6 - (D) M Veh (E) M Bex (F) F Veh (G) F Bex - and ubiquitin - (H) F Veh 





Figure 2. Immunoreactivity of glia is unchanged in APPswe/PS1ΔE9 mice following administration 
of bexarotene. (A) IBA1 levels in 11 month old male and female APPswe/PS1ΔE9 mice are 
unaffected by bexarotene treatment in both cortex [F(1,27)=2.231, p=0.147] and hippocampus 
[F(1,27)=2.127, p=0.156], and no significant effect of gender was detected [F(1,27)=0.665, 
p=0.422]. No significant interactions were detected. Error bars represent standard deviation. N-
values: non-transgenics (veh), males=5, females=5; APPswe/PS1ΔE9, males: Bex =8, Veh=7, 
females: Bex=5, Veh=3. Representative images of IBA1 staining and microglial morphology in 
(B) F tg Veh, (C) F tg Bex, (D) M Tg Veh and (E) M Tg Bex. Scale bars = 500 um large images 
and 50um on inserts. Morphology shows an amoeboid (active) state with clusters of activated 
microglia in APPswe/PS1ΔE9 animals (B,D). This morphology and clustering appears unchanged by 





Figure 3. Bexarotene fails to produce an effect on context-dependent or CS-dependent freezing 
behavior in APPswe/PS1ΔE9 mice. Percent of time spent freezing was measured to quantify long 
term fear memory. (A) In the training session, APPswe/PS1ΔE9 mice receiving bexarotene treatment 
demonstrated similar levels of context-dependent freezing compared to their vehicle-treated 
counterparts [F(7,44)=3.905, p=0.002; Tukey: male nontg p=1.000, male tg p=0.182, female 
nontg p=0.999, female tg p=1.000]. In the context-dependent testing session, no significant 
differences were detected among any of the groups [F(7,44)=1.794, p=0.113]. (B) Analysis of 
CS-dependent fear responses show no significant effect of bexarotene on freezing behavior in 
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APPswe/PS1ΔE9 male or female mice. A significant gender difference was detected between males 
and females in both non-transgenic and APPswe/PS1ΔE9 animals treated with vehicle [main effect 
of gender F(1,15)=23.506, p<0.0005; main effect of genotype F(1,15)=1.898, p=0.189, no 
significant interaction; females [M=42.006,SD=17.65] show lower levels of freezing than males 
[M=76.260,SD=10.50]. These gender-related differences were not observed in mice treated with 
bexarotene [males M=48.79, SD=20.71; females M=54.55, SD=21.48; main effect of sex 
F(1,27)=0.630, p=0.434; main effect of genotype F(1,27)=1.388,p=0.249; no significant 
interaction]. The condition of equality of variances was not met for this test. For all parts, error 
bars represent standard deviation. N-values females: nontg-veh=4, AP-veh=7, nontg-bex=8, AP-
bex=13. N-values males: nontg-veh=4, AP-veh=4, nontg-bex=6, AP-bex=5. 
 
 
Figure 4. Context-dependent freezing in APPswe/PS1ΔE9 female mice and non-transgenic 
littermates following a high-sensitivity conditioning protocol. A deficit is not yet present in 
APPswe/PS1ΔE9 females at 5 months of age [F(1,17)=0.684, p=0.420]. Context-dependent freezing 
deficits are detectable in APPswe/PS1ΔE9 females at 8 months of age [*F(1,17)=5.943, p=0.026], 
but do not persist to 10 months of age [F(1,18)=2.824, p=0.110]. N-values: 5 month-nontg=9, 
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APP/PS1=10, 8 month-nontg=8, APP/PS1=11, 10 month-nontg=12, APP/PS1=8. Error bars 
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